Sartorius Stedim Biotech SA

DIM: XPAR (FRA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
#K@LOCK|X@LOCK|kwD>cm

Sartorius Stedim Earnings: Guidance Unchanged on Strong Fundamentals; Shares Undervalued

Sartorius Stedim reported second-quarter results with 8% organic sales growth, excluding tariff surcharge compensation and currency effects, and underlying EBITDA margin expanding to 32.1% from 31.3% year over year. Management confirmed its full-year guidance.

Sponsor Center